Last reviewed · How we verify
DZP
DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system.
DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system. Used for Anxiety disorders, Seizure disorders, Acute alcohol withdrawal.
At a glance
| Generic name | DZP |
|---|---|
| Also known as | CDP7657 |
| Sponsor | UCB Biopharma SRL |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Benzodiazepines like DZP bind allosterically to GABA-A receptors and increase the frequency of chloride channel opening, leading to hyperpolarization of neurons and reduced neuronal excitability. This results in anxiolytic, sedative, muscle relaxant, and anticonvulsant effects. The drug is commonly used for anxiety disorders, seizure management, and acute alcohol withdrawal.
Approved indications
- Anxiety disorders
- Seizure disorders
- Acute alcohol withdrawal
- Muscle spasticity
Common side effects
- Sedation/drowsiness
- Dizziness
- Ataxia/coordination impairment
- Dependence/withdrawal risk
- Cognitive impairment
Key clinical trials
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHASE3)
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants (PHASE1)
- A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DZP CI brief — competitive landscape report
- DZP updates RSS · CI watch RSS
- UCB Biopharma SRL portfolio CI